RBC Capital Starts Apogee Therapeutics Inc (APGE) at Outperform

RBC Capital analyst Brian Abrahams initiates coverage on Apogee Therapeutics Inc (NASDAQ: APGE) with a Outperform rating and a price target of $60.00.

The analyst comments: "We are optimistic about APGE's potential to deliver clinically differentiated biologics. We believe preclinical, early clinical, and more recent Ph.II atopic dermatitis (AD) data demonstrated '777 and its combo therapies' advantageous PK properties, deep inflammatory signaling inhibition, and clinical activity. Along with sufficient de-risking from well-established targets, our positive KOL feedback on dosing convenience as a key element of clinical differentiation, and large revenue opportunities across several immunology and inflammation (I&I) indications, all underappreciated in the stock, in our view, we see share appreciation potential with upcoming clinical data. Initiating at Outperform, Speculative Risk with $60 price target."

For an analyst ratings summary and ratings history on Apogee Therapeutics Inc click here. For more ratings news on Apogee Therapeutics Inc click here.

Shares of Apogee Therapeutics Inc closed at $38.42 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• JPMorgan Starts Arashi Vision Inc (688775:CH) at Neutral